Role of miR‐200 family members in survival of colorectal cancer patients treated with fluoropyrimidines

Díaz, Tania; Tejero, Rut; Moreno, Isabel; Ferrer, Gerardo; Cordeiro, Anna; Artells, Rosa; Navarro, Alfons; Hernández, R; Tapia, Gustavo; Monzó, Mariano

doi:10.1002/jso.23572

Cited by 63 publications

(66 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Patients with lower miR-141 were more likely to have systemic lupus erythematosus (14 ). In cancers, higher concentrations of miR-141 in resected colorectal cancer patients were found to be associated with long-term and disease-free survival (15 ), on the one hand, but on the other, and seemingly more consistently, with poor outcomes including biochemical recurrence (16 ), increased metastasis (17 ) in prostate cancer, or poor prognosis in prostate cancer (18 ), hepatocellular carcinoma (19 ), and colon cancer (20 ). Results obtained in an identification cohort supported association of miR-141 with bladder cancer; however, this was not confirmed in a validation cohort (21 ).…”

Section: Diagnostic Specificity and Reproducibility Multiple Associatmentioning

confidence: 98%

Circulating MicroRNA Biomarker Studies: Pitfalls and Potential Solutions

2015

View full text Add to dashboard Cite

BACKGROUND Circulating microRNAs have been proposed as disease biomarkers that may aid in risk assessment, diagnosis, prognosis, and monitoring of treatment response. The perceived opportunity has loomed particularly large in neoplastic disease, where alterations in cancer cells are thought to be reflected in the extracellular space as affected cells release upregulated miRNAs or fail to release apparently downregulated species. Despite the promise of miRNA biomarkers, evaluation of the diagnostic specificity and reproducibility of reported markers suggests that realizing this promise remains a work in progress. CONTENTS This review examines issues of diagnostic specificity and reproducibility that have afflicted circulating miRNA studies. Surveying the breast cancer literature as an example, few miRNAs are reported consistently. Furthermore, it is posited that the assumptions underlying models of direct contributions of diseased tissue to biofluid miRNA profiles may not hold. Suggestions for improving diagnostic specificity and reliability are provided. SUMMARY To maximize the likelihood of return on investment as miRNAs continue to be evaluated as specific and clinically useful markers, a focus is needed on miRNAs found in specific carriers, such as extracellular vesicles. Alternative sampling techniques should be developed, and nonblood biofluids should be considered. Careful optimization and standardization of preanalytical and analytical methods is needed to ensure that future results, positive or negative, are reliable.

show abstract

Section: Diagnostic Specificity and Reproducibility Multiple Associatmentioning

confidence: 98%

Circulating MicroRNA Biomarker Studies: Pitfalls and Potential Solutions

2015

View full text Add to dashboard Cite

show abstract

“…Besides, experimental and clinical studies have cleared that hsa-let-7g and hsa-miR-181b are potential indicators for chemoresponse to S-1 based chemotherapy and miR-200a, miR-200c, miR-141, and miR-429 expression levels may identify CRC patients, including those with stage II disease, who are most likely to benefit from fluropyrimidine, an adjuvant chemotherapy agent (Nakajima et al, 2006;Diaz et al, 2014).…”

Section: Mirna As Marker For Treatment Response Predictionsmentioning

confidence: 99%

MicroRNAs in Colorectal Cancer: from Diagnosis to Targeted Therapy

Orang¹,

Barzegari²

2014

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

Colorectal cancer (CRC) is one of the major healthcare problems worldwide and its processes of genesis include a sequence of molecular pathways from adenoma to carcinoma. The discovery of microRNAs, a subset of regulatory non-coding RNAs, has added new insights into CRC diagnosis and management. Together with several causes of colorectal neoplasia, aberrant expression of oncomiRs (oncogenic and tumor suppressor miRNAs) in cancer cells was found to be indirectly result in up-or down-regulation of targeted mRNAs specific to tumor promoter or inhibitor genes. The study of miRNAs as CRC biomarkers utilizes expression profiling methods from traditional tissue samples along with newly introduced non-invasive samples of faeces and body fluids. In addition, miRNAs could be employed to predict chemo-and radio-therapy responses and be manipulated in order to alleviate CRC characteristics. The scope of this article is to provide a comprehensive review of scientific literature describing aberrantly expressed miRNAs, and consequently dysregulation of targeted mRNAs along with the potential role of miRNAs in CRC diagnosis and prognosis, as well as to summarize the recent findings on miRNA-based manipulation methods with the aim of advancing in anti-CRC therapies.

show abstract

“…A total of 2,534 patients from the United Kingdom, Germany, Spain, Poland, Japan, Sweden, Korea, Norway, Denmark, Italy, USA, China and Chinese Taiwan were diagnosed with a variety of cancers, including esophageal cancer [12,19,27], gastric cancer [16,25,28], colorectal cancer [8,20,29], rectal cancer [30], hepatocellular carcinoma [26], pancreatic cancer [11], lung cancer [13], breast cancer [15], diffuse large B-cell lymphoma (DLBCL) [18], bladder cancer [10], endometrial cancer [14,17], ovarian cancer [9,21,23,24] and prostate cancer[22]. In the primary reports, 11 studies showed a significant association between high miR-200c and poor prognosis [8,9,13,15,16,17,18,19,20,21,22], 9 provided the opposite result [10,11,24,25,26,27,29,30] and 5 found no prognostic value of miR-200c for tumor patients [12,14,20,23,28]. The expression of miR-200c was most often detected in tumor tissue samples, while five studies tested it in plasma or serum [15,16,19,20,27].…”

Section: Resultsmentioning

confidence: 99%

“…So 18 studies were identified in the 16 articles and were enrolled into the meta-analysis (Fig. 1) [10,11,12,13,14,15,16,17,19,20,22,24,25,27,28,29]. It has been previously reported that there was no association between serum miR-200c and miR-200c in primary tumor tissue [20], thus we performed a meta-analysis based on both tissue and circulating miR-200c independently.…”

Section: Resultsmentioning

confidence: 99%

“…Nearly half of these studies revealed a significant association between miR-200c overexpression and poor prognosis [8,9,13,15,16,17,18,19,20,21,22]. However, other studies reported an insignificant association or opposite conclusions [10,11,12,14,23,24,25,26,27,28,29,30]. The evidence from individual study is insufficient to conclude whether miR-200c can be used as a potent biomarker for prognosis.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Prognostic Role of Tissue and Circulating MicroRNA-200c in Malignant Tumors: a Systematic Review and Meta-Analysis

Shao¹,

Geng²,

Gu³

et al. 2015

Cell Physiol Biochem

View full text Add to dashboard Cite

Background: Recently, many studies have shown that microRNAs (miRNA) exhibit altered expression in various cancers and may serve as prognostic biomarkers. We performed a systematic review and meta-analysis to evaluate the prognostic role of miR-200c expression in different cancers. Methods: Studies were recruited by searching PubMed, Embase and the Cochrane Library (last search update was May 2014) and assessed by further quality evaluation. Results: A total of 25 studies dealing with various carcinomas were identified for systematic review. Among them, 18 studies were ultimately included in the meta-analysis. Our results indicated that the expression of tissue miR-200c was not associated with OS and PFS in various carcinomas; however, downregulation of tissue miR-200c did predict poor OS of patients with stage I disease (HR=0.41, 95% CI 0.25-0.68, P=0.001). Furthermore, overexpression of blood miR-200c was significantly related to poor OS and PFS (HR=3.07 95% CI 1.58-5.96 P=0.001, HR=2.26 95% CI 1.66-3.08 P<0.001, respectively), especially in patients with advanced disease. Conclusion: This systematic review and meta-analysis clarified that low expression of miR-200c in primary tissue was significantly associated with poor survival in cancer patients at early stage, whereas a high level of blood miR-200c predicted poor prognosis in patients with advanced tumors.

show abstract

Role of miR‐200 family members in survival of colorectal cancer patients treated with fluoropyrimidines

Abstract: miR-200a, miR-200c, miR-141, and miR-429 expression levels may identify CRC patients, including those with stage II disease, who are most likely to benefit from adjuvant chemotherapy.

Cited by 63 publications

References 33 publications

Circulating MicroRNA Biomarker Studies: Pitfalls and Potential Solutions

Circulating MicroRNA Biomarker Studies: Pitfalls and Potential Solutions

MicroRNAs in Colorectal Cancer: from Diagnosis to Targeted Therapy

Prognostic Role of Tissue and Circulating MicroRNA-200c in Malignant Tumors: a Systematic Review and Meta-Analysis

Contact Info

Product

Resources

About